Innate PharmaIPHA 41 Median PS Value is $0.23 as of Jun. 24, 2026, which is 65% below its 10-year median of 0.65. GuruFocus rates IPHA with a GF Score™ of 41/100 and a GF Value™ of $0.16 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 276 Biotechnology companies, Innate Pharma ranks worse than 97.46% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Innate Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.036. Innate Pharma's 10-Year median PS Ratio is 6.3889. Therefore, the Median PS Value for today is $0.23.
As of today (2026-06-24), Innate Pharma's share price is $1.90. Innate Pharma's Median PS Value is $0.23. Therefore, Innate Pharma's Price to Median PS Value for today is 8.26.
The historical rank and industry rank for Innate Pharma's Median PS Value or its related term are showing as below:
IPHA'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.4 Med: 0.65 Max: 8.43
Current: 8.26
During the past 13 years, the highest Price to Median PS Value of Innate Pharma was 8.43. The lowest was 0.40. And the median was 0.65.
IPHA's Price-to-Median-PS-Value is ranked worse than 97.46% of 276
companies
in the Biotechnology industry
Industry Median: 0.63
vs IPHA: 8.26
Innate Pharma (NAS:IPHA) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Innate Pharma's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
1.90
/
0.23
=
8.26
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innate Pharma Median PS Value Related Terms
Innate Pharma Median PS Value Historical Data
* Premium members only.
The historical data trend for Innate Pharma's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IPHA vs VRTX, REGN, ALNY: Median PS Value Comparison
For the Biotechnology subindustry, Innate Pharma's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innate Pharma Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innate Pharma's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Innate Pharma's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 6.3889.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Innate Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.036.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innate Pharma (IPHA) has a Median PS Value of $0.23 as of Jun. 24, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Innate Pharma and its competitors. This is 65% below median its historical median of 0.65. Over the past decade, Innate Pharma's Median PS Value has ranged from 0.40 to 8.43. According to the industry distribution chart, Innate Pharma ranks #269 out of 276 companies in the Biotechnology industry, placing it in the top 97.5%.
Is Innate Pharma's Median PS Value too high?
Innate Pharma's current Median PS Value of $0.23 is 65% below median its 10-year median of 0.65. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 8.43. The Biotechnology industry median Median PS Value is 0.63. Innate Pharma's value of $0.23 is 63.5% below this industry median. Based on the distribution chart, Innate Pharma ranks #269 out of 276 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Innate Pharma has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Innate Pharma's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innate Pharma ranks #269 out of 276 companies for Median PS Value. This places Innate Pharma in the lower half of its industry. The industry median Median PS Value is 0.63. Innate Pharma's value of $0.23 is 63.5% below this benchmark. Historically, Innate Pharma's own Median PS Value has ranged from 0.40 to 8.43 over the past decade. While the company's 10-year median is 0.65 vs. the industry median of 0.63, Innate Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 276 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innate Pharma's current Median PS Value of $0.23 is 63.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Innate Pharma and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innate Pharma's current Median PS Value is $0.23, which is 65% below median its own 10-year median of 0.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innate Pharma stock overvalued right now?
Based on GuruFocus' analysis, Innate Pharma (IPHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.16, compared to a current price of $1.90 — trading 1087.5% above its estimated fair value. The current Median PS Value is $0.23, which is 65% below median its 10-year median of 0.65 and 63.5% below the Biotechnology industry median of 0.63. Innate Pharma's overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Innate Pharma (IPHA), the current Median PS Value is $0.23 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innate Pharma (IPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued.
The current stock price of $1.90 is trading 1087.5% above its estimated GF Value™ of $0.16.
GuruFocus considers Innate Pharma to be Significantly Overvalued.
Key valuation signals for IPHA:
Median PS Value: $0.23 (65% below median its 10-year median of 0.65)
GF Value™: $0.16 vs. price of $1.90 (1087.5% above fair value)
Industry Position: 63.5% below the Biotechnology median (#269 of 276)
No single metric tells the full story. See the IPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
41GF Score
Get the complete analysis for IPHA
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPHA has been successfully added to your 
